This study is in progress, not accepting new patients
Study of AMV564 in Patients With AML
Acute Myeloid Leukemia AML treatment relapsed refractory phase 1 Leukemia Leukemia, Myeloid Leukemia, Myeloid, Acute Pembrolizumab AMV564 AMV564 in combination with pembrolizumab
Lead Scientist at UCSF
- Aaron Logan
The phone number listed above is my direct office number. If you prefer to contact the outpatient clinic, please call 415-353-2421. The clinic fax number is 415-353-2467.
- in progress, not accepting new patients
- Start Date
- Completion Date
- Amphivena Therapeutics, Inc.
- Phase 1
- Study Type
- Last Updated